IL-1 inhibitor

Here’s something that flew under the radar in the American gout community: In May 2026, China approved its first-ever IL-1β inhibitor specifically for acute gout flares. It’s called Fuxinqibai (development code: Efpelibikibart), marketed as Jinbeixin—and the clinical data is genuinely impressive. As someone who’s spent years tracking gout treatments for American patients, I find this … Read more